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Abstract
Background: Different presentations of treatment effects can affect decisions. However, previous studies have not
evaluated which presentations best help people make decisions that are consistent with their own values. We undertook a
pilot study to compare different methods for doing this.
Methods and Findings: We conducted an Internet-based randomized trial comparing summary statistics for
communicating the effects of statins on the risk of coronary heart disease (CHD). Participants rated the relative importance
of treatment consequences using visual analogue scales (VAS) and category rating scales (CRS) with five response options.
We randomized participants to either VAS or CRS first and to one of six summary statistics: relative risk reduction (RRR) and
five absolute measures of effect: absolute risk reduction, number needed to treat, event rates, tablets needed to take, and
natural frequencies (whole numbers). We used logistic regression to determine the association between participants’
elicited values and treatment choices. 770 participants age 18 or over and literate in English completed the study. In all, 13%
in the VAS-first group failed to complete their VAS rating, while 9% of the CRS-first group failed to complete their scoring
(p=0.03). Different ways of weighting the elicited values had little impact on the analyses comparing the different
presentations. Most (51%) preferred the RRR compared to the other five summary statistics (1% to 25%, p=0.074). However,
decisions in the group presented the RRR deviated substantially from those made in the other five groups. The odds of
participants in the RRR group deciding to take statins were 3.1 to 5.8 times that of those in the other groups across a wide
range of values (p=0.0007). Participants with a scientific background, who were more numerate or had more years of
education were more likely to decide not to take statins.
Conclusions: Internet-based trials comparing different presentations of treatment effects are feasible, but recruiting
participants is a major challenge. Despite a slightly higher response rate for CRS, VAS is preferable to avoid approximation of
a continuous variable. Although most participants preferred the RRR, participants shown the RRR were more likely to decide
to take statins regardless of their values compared with participants who were shown any of the five other summary
statistics.
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Introduction
There is a large literature on risk communication, including how
different presentations of risk influence understanding, perceptions
and decisions; and how information about risks is used in decisions
[1–12]. Systematic reviews have found that how information about
the effects of health care is presented impacts on how that
information is perceived and hypothetical decisions, although the
impact on real world decisions is less certain [6–11]. Differences in
presentations include positive versus negative framing, different
summary statistics (including relative and absolute measures of
effect), and different formats (numeric, verbal and graphical) [5–11].
One of the most consistent findings is that presenting a ‘‘relative risk
reduction’’ (RRR) as compared to an ‘‘absolute risk reduction’’
(ARR) or the ‘‘number needed to treat’’ (NNT) to express a
treatment effect results in more individuals perceiving the treatment
effect to be large and more decisions in favour of an intervention,
although the magnitude of the impact varies across different studies
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3693[5,10,11]. However, no previous studies have evaluated which
summary statistics best help people to make decisions that are
consistent with their own values. For example, although the RRR is
more persuasive than the ARR and NNT, this does not necessarily
mean that it is better or worse in terms of helping people make
decisions that are consistent with their values.
‘‘Values’’ here refers to the relative importance of the desirable
and undesirable effects of an intervention. Different people have
different values and these affect the decisions that they make. For
example, anticoagulation therapy reduces the risk of stroke and
increases the risk of serious gastrointestinal bleeding in patients with
atrial fibrillation. The relative importance of a stroke and serious
gastrointestinal bleeding varies widely (among both physicians and
patients) and these different values lead to different recommenda-
tions and decisions about whether to use anticoagulants [13].
Various models of decision making in health care stress the
importance of incorporating patients’ values for the possible
consequences of alternative interventions into a decision [14,15].
The consistency of a health care decision with the patient’s values,
along with various emotive, cognitive, and behavioural outcomes,
has been used to evaluate the quality of risk communication in
patient decision aids or between health care professionals and
patients [15–17]. For example, in 34 trials of decision aids for
screening decisions, two of the four trials that measured agreement
between values and choices found an improvement [18].
According to the normative concept of expected utility maximi-
zation [19], derived from the expected utility model of Daniel
Bernoulli, people should choose the option that gives the highest
expected utility. The utility (i.e. preference for or desirability) of
outcomes, such as different health states, is usually expressed as a
number ranging from zero to one, with death having a value of zero
and a fully healthy life having a value of one [20,21].
Expected utility theory has been questioned for a number of
reasons, which include problems with how utilities aremeasured and
observations that people often do not, in fact, choose to maximize
their utilities [22–26]. Nonetheless, it can still be argued that as the
expected utility for a decision, e.g. taking statin therapy, increases,
one would expect that, on average, increasing proportions of people
would choose to take the therapy if they were well informed. This
argumentdoesnotdependoneveryindividualchoosingtomaximize
his or her utilities. Some people may make decisions based on other
factors and it is difficult to accurately measure people’s utilities.
Nonetheless, amongst patients presented with the same choice
options with similar risks, one would expect some degree of
correlation between the values that individuals attach to the
desirable and undesirable consequences of a decision such as taking
medication and the likelihood that they would decide to take the
medication. In other words, one would expect that people for whom
the benefits of taking medication were less important and the
downsidesmoreimportant wouldbelesslikely, onaverage,to decide
to take medication than people for whom the benefits were more
important and the downsides were less important.
Several methods are used for eliciting the values that a person
places on health outcomes or other consequences of health care
decisions [27,28]. The three most commonly used methods that
generate a utility are the time trade-off, rating scales such as visual
analogue scales (VAS) and category rating scales (CRS), and the
standard gamble (SG), in that order [29]. The CRS is conceptually
a linear scale divided into evenly demarcated sections or
‘‘categories’’, thus forming a ‘‘category rating scale’’ [30]. The
standard gamble, which has been criticized because it is difficult to
explain to patients who do not find it intuitive [31], and the time
trade-off require interviews to administer [32], whereas the VAS
and CRS do not.
We report here the results of a pilot study of the Health
Information Project: Presentation Online (HIPPO). The goal of
the HIPPO project was to compare different ways of presenting
information about the effects of health care in order to determine
which presentations best help people to make decisions that are
consistent with their own values. The objectives of this pilot study
were to investigate the feasibility of conducting Internet-based
randomized trials comparing different risk reduction presentations;
to compare two methods (VAS and CRS) of eliciting values (i.e.
the relative importance of the desirable and undesirable
consequences of a decision); to explore approaches to combining
the elicited values to calculate a total value (‘‘relative importance
score’’); and to generate hypotheses and calculate sample size for a
confirmatory study comparing six summary statistics for commu-
nicating evidence of reduced risk of coronary heart disease (CHD)
with statin therapy for high cholesterol.
Methods
The protocol and CONSORT checklist for this study are
available as supporting information; see Protocol S1 and
CONSORT checklist S1. For a facsimile of this study’s Internet
site see Protocol S2.
We conducted an Internet-based randomized trial comparing
six summary statistics to express risk reduction (Figure 1). We
wanted to conduct Internet-based studies because we assumed that
this would be an efficient way to recruit participants and conduct
trials of different presentations. We first presented information
about the study and asked participants to give informed consent to
participate. We then asked them to imagine that they had elevated
cholesterol and needed to decide whether or not they would start
taking statin therapy. We presented textual information to the
participants about elevated cholesterol and the increased risk of
developing coronary heart disease (CHD), i.e. angina or having a
heart attack, during the next ten years; about the need to take a
statin pill each day and the side-effects of taking statins (Figure 2);
and that the estimated out-of-pocket cost for statin treatment was
US $50 per month.
Elicitation of values
Wechosetocomparetwo methodsofelicitingvalues,thecategory
rating scale (CRS) with five response options and the visual analogue
scale (VAS), range 0–100, that were simple to administer on the
Internet without participant training. Weelicited participants’ values
for three consequences of the choice to take statins (CHD, out-of-
pocket cost, and taking a pill every day) using both VAS (Figure 3)
and CRS (Figure 4). We randomized the participants to the order of
administration of these two methods.
Presentations
We then randomised participants a second time to view one of
six summary statistics expressing the reduced risk of CHD with
statin therapy (Box S1). We chose four summary statistics based on
the results of systematic reviews of previous studies [6], including
our own (unpublished data available from the authors): the RRR,
ARR, NNT and event rates (ER). These earlier studies showed
that individuals perceived the same effects to be greater when
stated as the RRR compared to the ARR. Studies comparing the
RRR and NNT found the RRR to be significantly more
persuasive. In studies comparing the ARR and NNT, there was
inconclusive evidence as to persuasiveness. In studies to find the
minimally important difference, the ARR produced 20% larger
differences in the medians than the NNT (25% versus 5%). Also,
the RRR was found to be more persuasive than ARR, NNT, and
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statistics, we presented ‘‘Tablets needed to take’’ (TNT) proposed
by Skolbekken [33] and the whole numbers presentation (WN)
proposed by Hollnagel [34] (natural frequencies) (Box S1). Of the
six summary statistics, RRR is a relative measure and the other
five are absolute measures of effect.
For our risk reduction presentation, we assumed a 10-year
baseline risk for CHD of 6% without statins [35], which is the
estimated risk for a person without other risk factors than a high
cholesterol level, and an RRR for CHD with statin therapy of 30
% [36]. We calculated the other summary statistics based on these
two values. Participants were given information, using their
allocated summary statistic, about the reduced risk of CHD with
statin therapy and then asked to indicate if they would decide to
start taking statins. The only allowed choices were ‘‘yes’’ or ‘‘no’’.
Participants could access explanations of heart disease, statins and
side effects using hyperlinks (Figure 2). They were not provided
any additional explanation of the summary statistics that they were
shown (e.g. RRR or ARR) (as shown in the Box S1).
Recruitment, eligibility and allocation
We contracted a vendor to send emails to 700,000 consumers in
the US who had ‘‘opted-in’’ to receive messages concerning health
and physical fitness. Participants were offered the option of
participating in a lottery to receive a $100 gift certificate as an
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doi:10.1371/journal.pone.0003693.g002
Figure 3. Visual analogue scales used to elicit participants’ values
doi:10.1371/journal.pone.0003693.g003
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analyses. Allocation to the order in which the two value-elicitation
methods were administered was block-randomized. Allocation to
one of the six summary statistics was also block-randomised, using a
looped sequence of 600 presentation assignments consisting of 100
blocks of six that was generated on http://www.randomization.com.
Data collection
We collected demographic data, including sex, age, years of
education, country of residence and profession after the participants
decided whether they would start taking statins. In addition, as
described in Appendix S1 and Appendix S2, we asked two questions
to assess their numeracy and three questions about their experience
with CHD and hypercholesterolemia to assess the salience of the
scenario (i.e. how relevant or important the hypothetical scenario
was likely to be to the participants). We then asked them questions
about their decision, including their level of confidence in their
decision (on a 5 point scale from ‘Not at all confident’ to ‘Extremely
confident’) and about themselves. Finally, we showed them all six
summary statistics and asked which one they preferred.
Figure 4. Category rating scales used to elicit participants’ values
doi:10.1371/journal.pone.0003693.g004
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were entered directly into a database where the data were stored
anonymously. Confidentiality of the data was ensured by not
collecting information that would make it possible to identify the
participants. Voluntary contact information that participants
supplied in order to request a report of the study results or to
participate in the lottery was stored in a separate database so it was
not possible to couple contact information and responses.
Statistical analyses
We assessed the relative merits of using VAS and CRS to elicit
values by comparing their distributions, response rates, and
expected utilities expressed as relative importance scores (RIS),
as described in Appendix S1. Spearman rank correlation
coefficients and box-plots were made for the elicited VAS and
CRS scores. To compare user acceptability, we used a Chi-
squared test to compare the 100% response rate for VAS (i.e.
completion of all 3 questions) when it was administered first and
the 100% response rate for CRS when it was administered first.
The analysis of the concordance of participants’ elicited values
and theirdecisionswas first performed using the elicitedVAS-values.
The three scales (CHD, cost and pills) were combined using four
approaches to weighting them to derive relative importance scores
for each participant. 1) We subtracted a rough estimate of the
expected utility (EU) of taking statins from the expected utility of not
taking statins, using the individual’s response to the VAS for CHD,
cost and pills and the probability of each of these consequences to
calculate RISEU_VAS. 2) We used principal component analysis
(PCA) to derive the weights used to calculate RISPCA_VAS.3 )W e
used logistic regression (LR) to derive the weights used to calculate
RISLR_VAS. 4) We used equal weights (ONE) to calculate
RISONE_VAS. In weighting schemes 2, 3 and 4, the relative
importance of the undesirable consequences (Pills and Cost) was
subtracted from the relative importance of the desirable conse-
quences(reducedriskofCHD).TheweightsarepresentedinTable1
and the formulae used to calculate them are described in Appendix
S1. The CRS-values were combined for the three scales using the
same four approaches to derive RIS values for each participant.
In order to compare the effects of the different summary
statistics on decisions in relation to elicited values, we performed
logistic regression analyses for each of the six groups and for the
pooled group of absolute summary statistics (i.e. all summary
statistics except for RRR). The participant’s decision was the
dependent variable and RIS was the predictor. We compared the
intercepts and slopes of the logistic regressions for each of the six
summary statistics and for the pooled absolute summary statistics.
We compared the likelihood of participants deciding to take statins
(expressed as log odds) across the six presentation groups at three
values of RIS in order to examine the impacts of the different
presentations for people with a range of values. The three values
were the points at which the regression line for all five of the
groups shown one of the absolute summary statistics crossed log
odds=0 (odds=1; i.e. where there was a 50% likelihood of their
deciding to take statins), and the 1
st and 3
rd quartiles of RIS.
We compared the four models using VAS and the four models
using CRS and used the c-statistic (a measure of concordance),
which is equal to the area under the receiver-operating
characteristic (ROC) curve when the outcome is binary, to
compare the discriminatory ability of the logistic regressions fitted
for all RIS models for each summary statistic, i.e. 48 c-estimates
[37]. A c-statistic of 1.0 indicates perfect accuracy, while a c-
statistic of 0.5 indicates a non-discriminatory test.
We explored the relationship between the decision of whether to
start taking statins in a logistic regression using RISONE_VAS and
presentation group as explanatory variables and the following
covariates: numeracy, salience, sex, professional background,
education and age.
Finally, we summarized the participants’ level of confidence and
satisfaction in their decisions; and the number and percent of
participants who preferred each of the six summary statistics,
which they indicated after they had seen all six.
We had no prior information as a basis for calculating a sample
size for this pilot study. The number of participants in each group
in the pilot study was therefore based on power calculations for
detecting a medium and a somewhat larger effect size for the
correlation between the VAS and CRS scores, as suggested by
Cohen [38]. Based on an effect size index (q) of 0.30 to 0.40, an
alpha of 0.05 to 0.10, and power of 0.70 to 0.80, we estimated that
we would need between approximately 80 and 140 participants
per group. No corrections for multiple testing were performed for
the tests reported here. The p-values should be interpreted with
caution and regarded as hypothesis generating.
Results
Feasibility
Five weeks after emails were sent to approximately 700,000
people, there were 1,492 log-ons to the study site, resulting in 782
complete records between 31 October and 4 December 2002. Of
these, one was excluded because age was less than 18. Eleven other
records with a VAS score for CHD of zero were excluded because
we assumed that the participants had either misunderstood the
Table 1. Weighting used to derive the relative importance
scores (RIS)
Weights
Relative importance Scores* CHD Pills Cost
RISEU
VAS 0.04/0.06 1/0 1/0
CRS 0.04/0.06 1/0 1/0
RISPCA
VAS 0.004 20.588 20.809
CRS 0.044 20.514 20.856
RISLR
VAS 0.011 20.013 20.005
CRS 0.125 20.476 20.162
RISONE
VAS 1 21 21
CRS 1 21 21
*VAS=visual analogue scale; CRS=category rating scale; RIS=relative
importance score. RISEU weights were based on an approximation of
participants’ expected utility (EU) for a decision (the expected utility of taking
statins minus the expected utility of not taking statins using the probabilities
shown in the table).
RISPCA weights were based on principle component analysis (PCA).
RISLR weights were based on logistic regression (LR).
RISONE weights were equal weights (ONE).
For RISEU, the estimate of the expected utility (EU) of taking statins was
subtracted from the estimate of the expected utility of not taking statins.
For RISPCA,R I S LR, and RISONE the undesirable consequences (Pills and Cost) were
subtracted from the desirable consequences (reduced risk of CHD).
The formulae used to calculate the weights used for each of the four
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checked whether participants completed the study more than
once. As we found no evidence for that, the remaining 770 records
were included in the analyses. The distribution of age, sex, country
of residence, years of education, profession, numeracy, and
salience score among the six presentation groups shows that the
randomization process worked well, providing comparable groups
(Table 2). Fifty-eight percent of the participants were women, 62%
were between 40 and 59 years old, 47 % had 17 or more years of
education and another 43% had 13 to 16 years of education, 84%
were from the U.S.A., 23% were health professionals and 17%
were scientists or engineers.
Elicitation of values
Of the 1492 log-ons, 998 people (67%) went as far as the first
value elicitation exercise, with 509 (51%) in the VAS-first group
and 489 (49%) in the CRS-first group. In all, 443 (87%) of the
VAS-first group completed all three visual analogue scales, while
446 (91%) of the CRS-first group completed all three category
rating scales (p=0.03). VAS and CRS correlated well for cost
(r=0.80) and pills (r=0.75). For CHD, the correlation was lower
(r=0.57). The median VAS scores for the five CRS categories for
CHD, cost and pills were approximately equidistant (Figure 5).
There was no difference in the distribution of the elicited raw
value scores (VAS and CRS) nor the RIS between the summary
statistics presentation groups (Figure 6).
From a visual inspection of the linear predictors produced by
regressing participants’ decisions on their relative importance score
(RIS) derived from VAS values (RISVAS) and on RIS derived from
CRS values (RISCRS), it appeared that there were no important
differences between them that would indicate that either VAS or
CRS was superior. Neither did it appear that any one of the RIS
Table 2. Participant characteristics
RRR n (%) ARR n (%) NNT n (%) ER n (%) TNT n (%) WN n (%) Total n (%)
n 131 120 131 135 121 132 770
Women 75 (57) 68 (57) 72 (55) 81 (60) 75 (62) 77 (58) 448 (58)
Age
18–29 7 (5) 10 (8) 6 (5) 10 (7) 8 (7) 10 (8) 51 (7)
30–39 16 (12) 11 (9) 15 (11) 16 (12) 17 (14) 16 (12) 91 (12)
40–49 35 (27) 33 (28) 32 (24) 43 (32) 36 (30) 33 (25) 212 (28)
50–59 45 (34) 44 (37) 46 (35) 40 (30) 40 (33) 49 (37) 264 (34)
60–69 21 (16) 13 (11) 20 (15) 19 (14) 14 (12) 23 (17) 110 (14)
70–79 7 (5) 4 (3) 11 (8) 6 (4) 4 (3) 0 32 (4)
over 80 0 5 (4) 1 (1) 1 (1) 2 (2) 1 (1) 10 (1)
Years of education
8 years or less 1 (1) 0 0 0 1 (1) 3 (2) 5 (1)
9–12 years 15 (11) 12 (10) 14 (11) 10 (7) 12 (10) 10 (8) 73 (9)
13–16 years 56 (43) 45 (38) 54 (41) 67 (50) 49 (40) 59 (45) 330 (43)
17 years or more 59 (45) 63 (53) 63 (48) 58 (43) 59 (49) 60 (45) 362 (47)
Country of residence
Canada 4 (3) 9 (8) 6 (5) 7 (5) 4 (3) 8 (6) 38 (5)
Germany 1 (1) 0 0 0 0 1 (1) 2 (0)
Norway 0 0 0 0 1 (1) 2 (2) 3 (0)
USA 110 (84) 97 (81) 113 (86) 109 (81) 104 (86) 111 (84) 644 (84)
other 16 (12) 14 (12) 12 (9) 19 (14) 12 (10) 10 (8) 83 (11)
Profession
GP or Health professional 34 (26) 29 (24) 31 (24) 27 (20) 23 (19) 33 (25) 177 (23)
Scientist or engineer 22 (17) 23 (19) 20 (15) 25 (19) 18 (15) 22 (17) 130 (17)
Numeracy
0 (low) 16 (12) 17 (14) 15 (11) 14 (10) 12 (10) 11 (8) 85 (11)
1 50 (38) 33 (28) 47 (36) 31 (23) 35 (29) 36 (27) 232 (30)
2 (high) 65 (50) 70 (58) 69 (53) 90 (67) 74 (61) 85 (64) 453 (59)
Salience
0 3 (2) 5 (4) 4 (3) 6 (4) 9 (7) 8 (6) 35 (5)
1 58 (44) 59 (49) 59 (45) 69 (51) 65 (54) 61 (46) 371 (48)
2 42 (32) 35 (29) 44 (34) 45 (33) 31 (26) 41 (31) 238 (31)
3 10 (8) 4 (3) 8 (6) 5 (4) 4 (3) 2 (2) 33 (4)
4 18 (14) 17 (14) 16 (12) 10 (7) 12 (10) 20 (15) 93 (12)
doi:10.1371/journal.pone.0003693.t002
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in Table 1, was better than the others at discriminating between
‘‘yes’’ and ‘‘no’’ decisions (Table 3 and Figure 7).
Decisions and responses
Altogether, 67% of the participants said they would start taking
statins. There was a statistically significant difference in the percent
of participants that decided to start taking statins across the six
groups, with the RRR group having the highest proportion (86%)
compared to the others (range 60% to 69%, p,0.0001) (Table 4).
There were no statistically significant differences across groups
regarding which summary statistic they preferred or in their
confidence in decisions (Table 4). However, of the 762 participants
who indicated their preferred summary statistic after viewing all
six, 393 (52%) preferred RRR, compared to the others (range 1%
to 25%, p=0.07) (Table 4).
The log odds for the four groups other than event rates (ER) and
RRR were similar at all values of the relative important scores
(RIS). The log odds for the RRR group was significantly
(p=0.0007) greater at all values of RIS (Figure 7), indicating that
the proportion of people deciding to take statins was larger than
for the other five presentations, independent of participants’
values. The RRR and the ARR groups had the steepest slopes
(b=0,016, 95% CI 0.006 to 0.025, and b=0,014, 95% CI 0.006
to 0.022, respectively). The ER group had the flattest slope
(b=0,005, 95% CI-0.002 to 0.011) and was the only group that
had a regression line that was not significantly different from zero.
For the pooled group of absolute summary statistics, the value of
RISONE_VAS was 248.5 at log odds for starting statins=0
(odds=1). At this value of RIS, the odds for the RRR group
was three times the odds for the other five groups (log odds 1.124,
odds 3.1). At the 1
st and 3
rd quartiles of RISONE_VAS (220 and 51)
the odds for RRR was respectively 3.7 and 5.8 times that of the
absolute summary statistics.
Explanatory factors
Sex (p=0.51) and age (p=0.40) were not statistically significant
explanatory factors for the decision to take pills. Nor was there a
significant difference between the proportion of all health
professionals or general practitioners (68%) and others (67%)
who decided to start taking statins (p=0.98). Scientists and
engineers, on the other hand, were less likely to decide to start
taking statins (56%) than both general practitioners and the rest of
the study population (69%, p=0.003). Participants with the
highest numeracy score (2) also decided to start taking statins
(62%) less often than those with a numeracy score of one (73%) or
zero (75%) (p=0.004). Similarly, participants with 17 or more
years of education were less likely to take satins (62%) compared to
those with 13–16 years of education (72%) and those with 12 or
less years of education (71%) (p=0.032).
We estimated the saliency of the scenario for participants based
on questions about whether participants had CHD, knew their
cholesterol level, and knew anyone who had experienced CHD
(see S1). Based on a summary of their responses to these three
Figure 5. Category rating scale (CRS) elicited values mapped on visual analogue scale (VAS) elicited values
doi:10.1371/journal.pone.0003693.g005
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doi:10.1371/journal.pone.0003693.g006
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participants (score 0 to 4), the more likely the participants were to
decide to take statins (p=0.01). Among those with high salience
scores (3 or 4) 76% would start taking statins compared to 71%,
63% and 54% for those with lower salience scores of two, one, and
zero respectively.
Discussion
The proportion of participants who chose to take statins was
highestfortheRRRgroup.Thiswasexpected,ashadbeenshownin
previous trials (and since confirmed in subsequent trials), that
presenting the RRR is more likely to result in decisions to
recommend or accept an intervention than the ARR or NNT [6–
12]. The RRR and ARR groups had the steepest slopes (Figure 4)
and theERgrouphad theflattestslopeand theonlyonethatwasnot
significantly different from zero, suggesting that decisions made in
this group were independent of the participants’ RIS values.
Based on these observations, we generated the following
hypotheses regarding the concordance between decisions and
values to be tested in a confirmatory study using the methods
developed in this pilot:
1. RRR results in a higher likelihood of deciding to start taking
statins across RIS values compared to the absolute summary
statistics.
2. The slope of the log odds of ARR is greater than the slope of
the other absolute summary statistics.
3. The concordance between decisions and values for ER is less
than for the other absolute summary statistics; i.e. that the slope
for the relationship between RIS values and the log odds of
deciding to take statins is not significantly different from zero
for ER (indicating that decisions were independent of the
participants’ elicited values), whereas it is positive (consistent
with what would be predicted) and significantly different from
zero for the other absolute summary statistics.
We estimated that we would need about 750 to 800 subjects in
each group to test these hypotheses based on the results of our pilot
study.
Feasibility
We found that the biggest challenge to this Internet-based trial
was recruiting a sufficient number of participants to achieve
adequate sample size, similar to what has been found for surveys
[39] and in a study similar to ours [40]. Only about 52% of log-ons
to our website resulted in complete, usable records compared to
72% in the latter study. The relative success of that study may be
attributable to intensive recruiting efforts on websites and in
printed materials dedicated to patients with the disease used in the
scenario and their carers.
A related problem with conducting this type of study on the
Internet is uncertainty about the applicability of the findings, as
discussed below. In this study we contracted for 700,000 e-mail
invitations to be sent out but we do not have data to compare the
characteristics of participants to those who were invited to
participate. Nor do we know how many invitations actually reached
their addressees or how many additional people participated who
were not among those to whom the invitations were sent.
Elicitation and weighting of values
We elicited participants’ values for three consequences that we
thought would be mostimportant to peoplemaking a decisioninthis
scenario. We did not attempt to identify other concerns that
individual participants may have had, and it is possible that they
might have taken other elements into consideration in making their
decisions. However, on average the likelihood that participants
would decide to start taking statins was correlated with the relative
importance of these three consequences, as predicted.
In measuring subjective change in pulmonary function, Guyatt
and colleagues found a seven-point category rating scale (CRS)
somewhat easier to use than the visual analogue score (VAS) and
responsiveness was comparable [41]. Intuitive grasp of the
minimal important difference guides the choice of how many
points to have on a scale for this purpose. Badia and colleagues
[42] found direct correspondence between participants’ ratings of
their overall health on a 5-point CRS and VAS, although the CRS
values were unevenly distributed along the VAS; and Schu ¨nemann
and colleagues found direct correspondence on 7-point health
related quality of life instruments [43].
The fact that we found correlation between VAS and category
rating scales (CRS) is not sufficient to justify the use of either one of
them. Using a 5-point CRS, it is difficult to interpret the results
when using three explanatory variables (CHD, pills, cost) as there
would be 125 different groups. Because there would be too few
observations for many of the groups, reliability of the resulting log
odds ratios could not be assumed. A solution to this is to treat the
CRS values as continuous variables. However, certain assumptions
must be fulfilled. It appears that the CRS fulfils the assumption
that the categories are ordered and the condition that they are
equidistant, if one uses their placement on the VAS-scale as
evidence of the subjective values of the categories. This does not
correspond with Badia’s findings [42] of uneven distribution.
However, we did find a clustering of the categories at the higher
end of the VAS, as reported by Badia. In addition, because we
found a clustering of individuals’ VAS around 10, 20, etc., we will
remove these labels from the VAS in future studies, leaving only
the low and high anchor points of ‘‘0’’ and ‘‘100’’ respectively.
The profiles of the estimates of the relative importance scores
based on the VAS and the CRS were similar. Being able to use a
continuous variable in the logistic regressions, instead of an
approximation using a categorical variable, outweighs the slightly
higher response rate of the CRS (4%), so we have decided to use
VAS in future studies.
Table 3. C-values for logistic regressions: Four models of
calculating RIS for visual analogue scales (VAS) scores and
categorical rating scale (CRS) scores*
RRR ARR NNT ER TNT WN Overall
Relative importance scores (RIS) based on VAS, c-values
RISEU 0.731 0.650 0.655 0.543 0.646 0.622 0.649
RISPCA 0.720 0.636 0.650 0.535 0.639 0.616 0.645
RISLR 0.751 0.709 0.652 0.576 0.627 0.611 0.656
RISONE 0.728 0.697 0.649 0.553 0.643 0.617 0.657
Relative importance scores (RIS) based on CRS, c-values
RISEU 0.794 0.647 0.694 0.598 0.659 0.629 0.667
RISPCA 0.772 0.635 0.685 0.582 0.662 0.621 0.660
RISLR 0.832 0.657 0.682 0.614 0.630 0.653 0.671
RISONE 0.769 0.665 0.666 0.587 0.642 0.630 0.660
*A c-statistic of 1.0 indicates perfect accuracy, while a c-statistic of 0.5 indicates




PLoS ONE | www.plosone.org 10 November 2008 | Volume 3 | Issue 11 | e3693As illustrated in Figure 4, there was little difference across the
four ways we used to derive the relative importance scores (RIS)
using the weights shown in Table 1. The C-values in Table 3 show
that any weighting method yields a model that discriminates
between a ‘‘yes’’ and ‘‘no’’ decision to start taking statins about as
well as any other, consistent with Dawes’ findings that ‘‘improper’’
linear models that use equal weighting are quite robust for making
clinical predictions [44]. Guided by the principle of parsimony, we
chose the simplest model (RISONE_VAS) for the subsequent HIPPO
studies, i.e. equal weights. The absolute RIS values are arbitrary
Figure 7. Log odds for deciding to start taking statins in relation to relative importance scores
doi:10.1371/journal.pone.0003693.g007
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However, the results of this study suggest that the RIS scores
provide a robust measure of the relative importance that
participants attach to the consequences of a decision for
comparisons within a study, regardless of the weights that are used.
Explanatory factors and applicability of the results
Participants with a scientific background, who were more
numerate, or who had more years of education were less likely to
decide to start taking statins. General practitioners and the general
public had the same likelihood to start taking statins, in contrast to
participants who classified themselves as scientists, who were less
likely to opt for statin therapy. The likelihood of deciding to start
statins also increased as the salience of the scenario increased. This
finding could be explained by the availability heuristic [45], which
suggests that as vividness or emotional impact increases (in this
case the salience of the scenario), the perceived probability of an
outcome increases (in this case CHD).
These findings suggest that the effects of different presentations
of risk may interact with these characteristics and that the
applicability of the results of trials such as this one might be limited
in relationship to these characteristics. Furthermore, it is uncertain
to what extent results from hypothetical scenarios apply to actual
decisions [7,46]. While the results of Internet-based studies such as
this one likely apply to printed information as well as electronic
information, the relevance of the results to personal communica-
tion is uncertain.
The applicability of the results to different populations is also
uncertain, particularly to less educated populations. Most (86%) of
the participants were from the U.S.A. and 47% had 17 years or
more of education. By comparison, only 8% of the U.S.
population had a master’s degree or higher (roughly comparable
to 17 years or more of education) in 2002 (http://www.census.
gov/population/socdemo/education/ppl-169/tab11.xls). In light
of the finding that highly educated participants appeared less likely
than others to decide to start taking statins across presentations, it
is possible that they would also respond differently to different
presentations, thereby limiting the applicability of findings from
Internet-based studies, such as this, to populations with less
education. Similarly, the applicability of the results to populations
for whom the scenario is more or less salient may be limited.
A systematic review of the impact of different presentations on
treatment decisions by patients found that, although good quality
studies were limited in number, the results suggested that framing
effects were influenced by various effect modifiers [10]. Malenkaand
colleagues [47] found that those with higher education or being
treated for the condition were more likely to prefer medication when
presented the RRR, and Misselbrook and colleagues [48] found that
those with hypertension or taking other chronic medications (which
could be considered as indicators of saliency) were more likely to
accepttreatment when presented the RRR,although therewasnot a
significant difference in responses in relationship to familiarity with
stroke. Other studies that examined education as a possible effect
modifier for framing effects did not find a significant effect [49,50].
Table 4. Decision to start taking statins and other responses
RRR n (%) ARR n (%) NNT n (%) ER n (%) TNT n (%) WN n (%) Total n (%)
n 131 120 131 135 121 132 770
Decision to take statins (yes) 113 (86) 75 (63) 83 (63) 81 (60) 84 (69) 81 (61) 517 (67)
Preferred presentation
Not stated 0 (1) (1) (2) (3) (1) 8 (1)
RRR (59) (56) (49) (53) (40) (48) 393 (51)
ARR (4) (3) (2) (4) (3) (5) 29 (4)
NNT (3) (4) (6) (4) (4) (5) 34 (4)
ER (12) (12) (10) (19) (16) (13) 104 14)
TNT 0 (2) (4) 0 (2) (1) 11 (1)
WN (22) (22) (28) (18) (32) (27) 191 (25)
Sure of rated relative importance
1 (low) 0 1 (1) 0 1 (1) 0 0 2 (0)
2 7 (5) 4 (3) 4 (3) 7 (5) 8 (7) 6 (5) 36 (5)
3 15 (11) 16 (13) 14 (11) 13 (10) 18 (15) 14 (11) 90 (12)
4 44 (34) 51 (43) 44 (34) 53 (39) 38 (31) 54 (41) 284 (36)
5 (high) 65 (50) 48 (40) 69 (53) 61 (45) 57 (47) 58 (44) 358 (47)
Confidence in decision
Low confidence 30 (23) 31 (26) 26 (20) 35 (26) 30 (25) 37 (28) 189 (25)
High confidence 101 (77) 89 (74) 105 (80) 100 (74) 91 (75) 95 (72) 581 (75)
Understanding of information
1 (low) 0 0 0 0 2 (2) 0 2 (0)
2 4 (3) 8 (7) 4 (3) 6 (4) 4 (3) 3 (2) 29 (4)
3 15 (11) 9 (8) 16 (12) 14 (10) 10 (8) 9 (7) 73 (9)
4 28 (21) 33 (28) 25 (19) 38 (28) 34 (28) 33 (25) 191 (25)
5 (high) 84 (64) 70 (58) 86 (66) 77 (57) 71 (59) 87 (66) 475 (62)
doi:10.1371/journal.pone.0003693.t004
Evaluating Risk Communication
PLoS ONE | www.plosone.org 12 November 2008 | Volume 3 | Issue 11 | e3693Conclusions
It is feasible to conduct randomized trials of different ways of
presenting the effects of health care on the Internet. However,
recruitment of participants is a major challenge. In addition,
although randomisation ensures comparable groups, questions
may still remain about the applicability of the results to specific
populations. Visual analogue scales appear to function well for
eliciting the relative importance of the consequences of a decision.
Our approach to comparing different ways of presenting
information about the effects of health care is, so far as we are
aware, the first attempt to evaluate the extent to which different
presentations help people to make decisions that are consistent with
their own values. The validity of our approach is supported by the
fact that the likelihood of participants deciding to start taking statins
increased as predicted in relationship to the relative importance they
placed on the advantages and disadvantages of taking statins; and by
the consistency of our results with what could be hypothesised based
onpreviousstudies,i.e.thatparticipantswhowereshowntherelative
risk reduction were more likely to decide to take statins regardless of
their values compared with participants who were shown any of the
five absolute summary statistics.
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